THE TAPE

Zai Lab Limited American Depositary Shares

$23.47▼ −4.59%
Last close
Relative strength
56RS
of 99, against every stock▲ +15 on the month
Powering up
Unconfirmed
+12.0%
six months against Pharmaceutical Preparations
52-week range
−19.1%
from the high
$15.96$29.02
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth WEAKProof PENDING
Quarter to Sep 30, revenue −7% on a year ago
Why it is on no screen

ZLAB is off the screens on 2 checks.

A base has formed15.6 weeks, from 16.26 to 25.28.
Long enough to count15.6 weeks against 3 needed.
Shallow enough35.7% deep against 35% allowed.
Close to its pivot-7.2% from the pivot; listed down to -20%.
Relative strengthRS 56 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$21.14
-9.9% · tested 5× · last 9 sessions ago
Resistance above
$23.70
+1.0% · tested 3× · last 27 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Zai Lab Limited American Depositary Shares is not on any of the screens right now. Its relative strength rating is 56, and it sits in Pharmaceutical Preparations.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-3.1%
Three months against its industry
+6.0%
Six months against its industry
+12.0%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 9.6% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$441.7M
-6.8% year on year
Operating margin
-63.0%
Net margin
-44.9%
Free cash flow
$-163.3M
-5.6% of market cap
Price to sales
6.60×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Shrinking and burning cash: the quarter weakens the case.
Revenue
$108.2M
+1.8% QoQ · -6.8% YoY
Gross margin
—
Net income
−$46.1M
Loss
Free cash flow
−$58.8M
Burning · 9q runway

What the numbers say

  • Weak: Revenue -6.8% year over year, +1.8% on the quarter
  • Weak: Net loss $46M, narrower than $51M last quarter
  • Weak: Burning cash: operating cash flow -$58M, free cash flow -$59M, better than -$65M last quarter · 9 quarters of cash at this burn
  • Weak: Growth externally funded: capex $947K against operating cash flow -$58M
  • Good: Net cash $297M · cash $550M
Revenue by quarter
Free cash flow
Net income
shares +1.9% in a year · net cash $297.3M

What is not obvious

  • Weak: Stock compensation $11M added back against negative operating cash flow
  • Weak: Interest $2M a quarter against an operating loss: the debt is carried by the balance sheet, not operations
Final read
Growth: WEAK · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is revenue growth: revenue -6.8% year over year, +1.8% on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
In the news
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?The Motley Fool · 4 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What analysts expect
Strong buy2
Buy9
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Zai Lab Limited American Depositary Shares (ZLAB) — The Tape